The S-1 is a routine resale registration, but the underlying Strata Agreement creates a structural overhang: ClearThink can sell shares at 85% of the lowest closing price over 10 days, incentivizing short-term selling pressure. Monitor the company's ability to draw down the full $5.0M commitment — each draw will dilute existing holders and depress the stock. The going-concern risk and OTC Pink listing make this a high-risk, distressed-equity story.
Executive Summary
VSee Health filed an S-1 registration statement to register up to 3,540,000 shares of common stock for resale by ClearThink Capital Partners, LLC, the selling stockholder under a $5.0 million Strata Purchase Agreement. The company is a post-reverse-stock-split, OTC-traded telehealth firm that recently divested its VSee Lab subsidiary, has an accumulated deficit of $84.2 million, and received a going-concern opinion from its auditor. The filing itself is a routine resale registration — the company receives no proceeds from the resale but may receive up to $5.0 million from future share sales to ClearThink at an 85% discount to market.
Key Financial Metrics
Key Facts
- S-1 registers up to 3,540,000 shares for resale by ClearThink under a $5.0M Strata Purchase Agreement (purchase price = 85% of lowest closing price over 10 trading days).
- Company has accumulated deficit of $84,169,712 as of June 30, 2026; net loss from continuing ops of $4,344,228 for H1 2026.
- Independent auditor included a going-concern explanatory paragraph for FY 2025.
- Common stock delisted from Nasdaq on Aug 6, 2026; now trades on OTC Pink under VSEE.
- Revenue grew 53% YoY to $3.44M in H1 2026, but gross margin collapsed from 63% to 27% due to lower-margin teleradiology mix.
- Cash balance fell from $5.05M (Dec 31, 2025) to $454,151 (June 30, 2026); operating cash burn of $2.5M from continuing ops in H1 2026.
- 1-for-80 reverse stock split effective Sept 23, 2026; stock closed at $2.18 on Sept 30, 2026.
- Material weaknesses in internal controls over financial reporting identified.
Financial Impact
Up to $5.0M in potential equity-line funding at 85% of market price; existing shareholders face severe dilution from up to 3.5M new shares (vs 806K outstanding).
Risk Factors
- Severe dilution from up to 3.5M shares issuable under the Strata Agreement (vs 806K shares outstanding).
- Going-concern uncertainty; cash burn of $2.5M in H1 2026 with only $454K cash on hand.
- OTC Pink listing limits institutional interest and liquidity.
- Material weaknesses in internal controls increase risk of financial restatements.
- Customer concentration: one customer = 43% of H1 2026 revenue.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001185185-26-004518 |
| Document: vseeex10-81.htm | 0001185185-26-004518 |
| Document: vseeex5-1.htm | 0001185185-26-004518 |
| Document: 0001185185-26-004518-index-headers.html | 0001185185-26-004518 |
| Document: 0001185185-26-004518-index.html | 0001185185-26-004518 |
| Document: 0001185185-26-004518.txt | 0001185185-26-004518 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | S-1 | $1.98 $1.95 | ▲ +1.52% | ▲ +2.68% | $1.70 (+14.14%) |
Jun 26, 2026 17w ago | 8-K | $0.1109 $0.1130 | ▼ −1.89% | ▼ −0.51% | $1.70 (−1432.91%) |
Jun 11, 2026 19w ago | 8-K | $0.1420 $0.1156 | ▲ +18.59% | ▲ +19.26% | $1.70 (−1097.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers